Viragen Licenses 'Anti-CD55 Antibody' Cancer Therapy from Cancer Research Technology
"Based on the results of our promising preliminary in vitro evaluations utilizing this novel anti-cancer agent, we are pleased to report that we have exercised our option to acquire exclusive global development and marketing rights to the anti-CD55 antibody," stated Viragen's President and CEO, Mr. Charles A. Rice. "As a monotherapy, or in combination with other anti-cancer therapies, we believe this antibody represents a potentially efficacious treatment for a broad range of tumors, including breast, ovarian and colorectal cancers."
Viragen recently reported that the anti-CD55 antibody, known as VG102, was able to enhance the action of Rituxan® (Rituximab), resulting in the significant increase in the destruction of cancer cells in vitro, indicating the potential of the agent to be used effectively in combination with other therapies.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.